vendredi 17 novembre 2017

Onco Actu du 17 novembre 2017

1. Biologie

Growing tiny tumours in the lab could help treat cancer [The Economist]

2. Etiologie

Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer [Reuters]

3.3 Prévention - Vaccins

Media coverage of HPV vaccine increased reports of adverse events – Expert Reaction [Science Media Centre]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering [EndPoints]

5.10 Traitements - Essais

ASCO Expands TAPUR Study Enrollment After Promising Initial Treatment Outcomes Seen [ASCO]

5.12.2 Immunothérapies - CAR-T

At Seattle Children’s, Another Piece of Ambitious CAR-T Plan in Place [Xconomy]

Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma [Celgene]

FDA, EMA put a star CAR-T from bluebird and Celgene on the VIP list [EndPoints]

Cancer immunotherapy company tries to explain deaths in recent trial [Science]

Message from the President [EBMT]

5.12.8 Immunothérapies - Economie

How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas [FiercePharma]

5.3.4 Traitements - AMM (FDA, EMA)

Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma [Pfizer]

Roche nabs blockbuster FDA approval for Hemlibra, big label expansion for Gazyva [FiercePharma]

FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma [Roche]

FDA expands approval of Sutent to reduce the risk of kidney cancer returning [FDA]

FDA backs Roche's Gazyva in first-line follicular lymphoma [Reuters]

FDA expands approval for Pfizer cancer drug Sutent [Reuters]

5.4 Traitements - Economie

Two breast cancer drugs get NHS approval [Cancer Research UK]

5.8.2 ASH - Pharma

Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH? [EndPoints]

6. Lutte contre les cancers

National organizations support outreach efforts for NIH’s All of Us Research Program [NIH]

6.11 Patients

This Is What Sex After Gynecological Cancer Is Really Like [Self]

6.4 Médico-éco

High-value oncology practices include “support for the patient journey” [Stanford Medicine]

6.6 Publications

The original preprint system was scientists sharing photocopies. Then journal publishers screamed [STAT]

Why we should care that many editors of top medical journals get healthcare industry payments [HealthNewsReview]

6.7.1 Bioinformatique

AI Can Be Made Legally Accountable for Its Decisions [MIT Technology Review]